Locally Advanced and Metastatic Melanoma. Relevant disclosures 6/23/2018. What is the median survival of metastatic melanoma? Abel D.

Size: px
Start display at page:

Download "Locally Advanced and Metastatic Melanoma. Relevant disclosures 6/23/2018. What is the median survival of metastatic melanoma? Abel D."

Transcription

1 Locally Advanced and Metastatic Melanoma Abel D. Jarell, MD, FAAD Adjunct Dartmouth School of Medicine, Hanover, NH Northeast Dermatology Associates, Portsmouth, NH Relevant disclosures What is the median survival of metastatic melanoma? A. Less than 1 year B. Less than 5 years C years D. Greater than 10 years 1

2 What is the median survival of metastatic melanoma? A. Less than 1 year B. Less than 5 years C years D. Greater than 10 years What is the 5-year survival rate of metastatic melanoma? A. < 1% B. < 5 % C % D % What is the 5-year survival rate of metastatic melanoma? A. < 1% B. < 5 % C % D % 2

3 Locally Advanced and Metastatic Melanoma Diagnosis Manageable melanoma Role of the sentinel lymph node Metastatic melanoma What happens to your patient when you refer them? 3

4 Manageable 4

5 Wide local excision with 1-cm margins 5

6 Surgical Oncology Medical Hematology Oncology Then what? Surgical Oncology To Lymph node or Not to Lymph node? 6

7 Indication for SLN in MM Benefit exceeds risk Complication rate of SLN is less than 10% Bleeding, infection, seroma, rarely DVT or lymphedema Greater than 5% risk of SLN positivity AJCC 8 th ed pt1b Any depth with ulceration >0.8mm without ulceration What is a Sentinel? A node upon which a lymph vessel originating in the tumor drains directly Predicts additional LN basin involvement 7

8 Tracer Injection Intradermal injection cm from scar or tumor margin 2 wheals on extremities 4 wheals on H&N or trunk Left Mid Back 8

9 Variables Type and dose of tracer (size of particles) Volume of tracer injected Timing of imaging Gamma probes vary General or local anesthesia 9

10 What Can Go Wrong? SN can be missed True SN may not be radioactive or blue Tumor obstructs lymph flow Not every radioactive or blue node is a SN First node visualized may not be the only SN Nearest node is not always the node that drains the tumor Initial wide excision alters lymph flow What Can Go Wrong? Gamma probe use requires intense training Surgical learning curve FN rate drops from 10% in first 25 cases to 5% for following cases Cautery or crush obscures the subcapsular space 10

11 METASTATIC MELANOMA Historically has a poor prognosis Median survival ~ 6-9 months 5-year survival < 5% METASTATIC MELANOMA Historically has a poor prognosis Prior to 2011, no FDA-approved therapy shown to prolong survival METASTATIC MELANOMA The pace of progress Ipilimumab 2011 Vemurafenib 2011 Dabrafenib 2013 Trametinib 2013 Pembrolizumab 2014 Nivolumab 2015 Talimogene laherparepvec 2015 Many promising agents in clinical trials 11

12 FDA-approved medications for advanced melanoma Targeted kinase inhibitors BRAF inhibitors ( vemurafenib, dabrafenib) MEK (trametinib, cobemetinib) Immunotherapy agents Ipilimumab PD-1 inhibitors (nivolumab, pembrolizumab) Talimogene laherparepvec/t-vec Vemurafenib Selective BRAF kinase inhibitor (V600E Mutation) ve = V600E mu = mutation rafenib = RAF inhibitor Approved for treatment of unresectable or metastatic melanoma with BRAF V600E mutation August 2011 N Engl J Med 2014; 370:e22 12

13 BRAF mutation 50-60% of all melanomas harbor mutations at codon 600 Valine (V) to glutamic acid (E) substitution most common mutation at position 600 = V600E (90%) 2 nd most common mutation is V600K (valine lysine) Mutation results in constitutive activation of MAP kinase signaling pathway = dysregulated tumor growth V600E mutations confer increased sensitivity to BRAF inhibitors (vemurafenib, dabrafenib) 13

14 Vemurafenib 80% of patients with BRAF V600E will have at least a partial response within weeks The majority of patients will experience relapse Secondary mutations will develop within melanomas in response to therapy Median time to progression 6-7 months Few long term responders How is BRAF testing performed? PCR-based V600E mutation test Used on formalin-fixed, paraffin-embedded tissue Sensitive detection of the BRAF V600E mutation May also detect other mutations, such as V600D, V600K, and V600R Additional options for BRAF testing Targeted next generation sequencing panels Used on formalin-fixed, paraffin-embedded tissue 14

15 Vemurafenib Side effects 40% of patients require dose reduction Systemic manifestations Fatigue, arthralgias common 15

16 16

17 FDA Approved medications for advanced melanoma Targeted kinase inhibitors BRAF inhibitors (vemurafenib, dabrafenib) MEK (trametinib, cobimetinib) Immunotherapy agents Ipilimumab PD-1 inhibitors (nivolumab, pembrolizumab) Talimogene laherparepvec (T-VEC) 17

18 Ipilimumab 4 IV doses, 3 weeks apart Effect often seen toward the end of dosing % of patients will respond But many of these patients will have a durable response Ipilimumab Toxic side effects General activation of the immune system, leading to immune-related issues Diarrhea Hypophysitis Skin manifestations Morbilliform eruption Pruritus Vitiligo 18

19 Nivolumab and Pembrolizumab IV dosing, indefinitely (?) Higher response rate than ipilimumab 30% will have objective response More rapid response Fewer side effects 10% discontinued pembrolizumab in clinical trials 19

20 20

21 21

22 22

23 Prognosis and GEP Established use in uveal MM 31 gene assay in cutaneous MM Stage I and II 23

24 Combined SLN and GEP Metastatic melanoma with a V600E mutation could successfully be treated with: A. Ipilimumab B. Vemurafenib C. Nivolumab D. TVEC 24

25 Metastatic melanoma with a V600E mutation could successfully be treated with: A. Ipilimumab B. Vemurafenib C. Nivolumab D. TVEC Questions? 25

Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology

Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy

More information

Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures

Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory

More information

Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)

Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Provincial Cancer Care Conference 2018 Ralph P.W. Wong MD FRCPC St Boniface Site Director

More information

Melanoma: Therapeutic Progress and the Improvements Continue

Melanoma: Therapeutic Progress and the Improvements Continue Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic

More information

Update on Genetic Testing for Melanoma

Update on Genetic Testing for Melanoma Update on Genetic Testing for Melanoma Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania February 18, 2018 AAD

More information

Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology

Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing

More information

Innovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD

Innovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications

More information

Modern therapy in oncology Metastatic melanoma

Modern therapy in oncology Metastatic melanoma Modern therapy in oncology Metastatic melanoma Anna Buda-Nowak Oncology Department; University Hospital in Cracow Melanoma Malignant skin neoplasm derived from neuroectodermal melanomatous cells. The incidence:

More information

Melanoma 10/12/18 Justin J. Baker, M.D.

Melanoma 10/12/18 Justin J. Baker, M.D. Objectives Review Incidence Risk Factors for Development Detection 10/12/18 Justin J. Baker, M.D. Treatment of Surgery Medicine Radiation What is Incidence Cancer of Melanocytes Melanocytes are normal

More information

NCCN Guidelines for Cutaneous Melanoma V Meeting on 06/20/18

NCCN Guidelines for Cutaneous Melanoma V Meeting on 06/20/18 ME-1, ME-3, ME-B Submission from Castle Biosciences, Inc (05/30/18) to consider inclusion of the DecisionDx-Melanoma test in the guidelines as a prognostic test that provides stratification according to

More information

New paradigms for treating metastatic melanoma

New paradigms for treating metastatic melanoma New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall

More information

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved

More information

Update on Melanoma Treatment. Tara C Mitchell, MD

Update on Melanoma Treatment. Tara C Mitchell, MD Update on Melanoma Treatment Tara C Mitchell, MD Overview Immune therapy update Targeted therapy update New concepts in treating melanoma What is the immune system? A complex network of protective cells

More information

Melanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division

Melanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially

More information

Metastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds

Metastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds Metastatic Melanoma Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds Case Presentation 77 year old male with previous history of scalp melanoma and thyroid

More information

Approaches To Treating Advanced Melanoma

Approaches To Treating Advanced Melanoma Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy BRAF Gene Variant Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_variant_testing_to_select_melanoma_or_glioma_patients_for_targeted_

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy BRAF Gene Mutation Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_mutation_testing_to_select_melanoma_or_glioma_patients_for_targeted_

More information

Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania

Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions

More information

Topics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:

Topics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes: Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of

More information

I have no relevant conflicts of interest to disclose. John T. Seykora MD PhD Departments of Dermatology & Pathology and Laboratory Medicine

I have no relevant conflicts of interest to disclose. John T. Seykora MD PhD Departments of Dermatology & Pathology and Laboratory Medicine Molecular Characterization of Stage 1-3 Melanoma: Are we close to accurate prognostication and prediction? I have no relevant conflicts of interest to disclose. John T. Seykora MD PhD Departments of Dermatology

More information

Treatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC

Treatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off

More information

6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)

6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC) Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab

More information

Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin

Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors

More information

Talimogene Laherparepvec (T-VEC) at the SCCA: an update

Talimogene Laherparepvec (T-VEC) at the SCCA: an update Talimogene Laherparepvec (T-VEC) at the SCCA: an update Jennifer M. Gardner, MD Assistant Professor, Division of Dermatology University of Washington jen1110@uw.edu Northwest Melanoma Symposium: Science

More information

Subject: Cobimetinib (Cotellic ) Tablet

Subject: Cobimetinib (Cotellic ) Tablet 09-J2000-53 Original Effective Date: 03/15/16 Reviewed: 11/14/18 Revised: 12/15/18 Subject: Cobimetinib (Cotellic ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

INIBITORE di BRAF nel MELANOMA

INIBITORE di BRAF nel MELANOMA INIBITORE di BRAF nel MELANOMA Paola Agnese Cassandrini Negrar,29 novembre 2016 BRAF is a serine/threonine protein kinasi encoded on chromosome 7q34 that activates the MAP kinase/erksegnaling pathway

More information

Disclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION

Disclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION 8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,

More information

CombiRT in Metastatic Melanoma Trial

CombiRT in Metastatic Melanoma Trial CombiRT in Metastatic Melanoma Trial An open-label, single-arm, phase I/II, multicenter study to evaluate the safety and efficacy of the combination of dabrafenib, trametinib and palliative radiotherapy

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Trametinib (Mekinist) for Metastatic Melanoma October 22, 2013

pan-canadian Oncology Drug Review Final Clinical Guidance Report Trametinib (Mekinist) for Metastatic Melanoma October 22, 2013 pan-canadian Oncology Drug Review Final Clinical Guidance Report Trametinib (Mekinist) for Metastatic Melanoma October 22, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

More information

What You Need to Know about Advanced Melanoma Therapies Targeted Approaches

What You Need to Know about Advanced Melanoma Therapies Targeted Approaches 2018 AAD Annual Meeting, San Diego, CA What You Need to Know about Advanced Melanoma Therapies Targeted Approaches Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion & Melanoma

More information

Systemic implications of Melanoma. Melanoma 2/4/2018. Cancer USA Epidemiology: Incidence and Mortality. Skin Cancer USA

Systemic implications of Melanoma. Melanoma 2/4/2018. Cancer USA Epidemiology: Incidence and Mortality. Skin Cancer USA Systemic implications of Melanoma Darrell S. Rigel, MD MS Clinical Professor of Dermatology New York University Medical Center New York, New York DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Darrell

More information

Radionuclide detection of sentinel lymph node

Radionuclide detection of sentinel lymph node Radionuclide detection of sentinel lymph node Sophia I. Koukouraki Assoc. Professor Department of Nuclear Medicine Medicine School, University of Crete 1 BACKGROUND The prognosis of malignant disease is

More information

Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1

Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1 Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND

More information

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2. Sullivan et al. Journal for ImmunoTherapy of Cancer (2018) 6:44 https://doi.org/10.1186/s40425-018-0362-6 POSITION ARTICLE AND GUIDELINES Open Access An update on the Society for Immunotherapy of Cancer

More information

BRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy

BRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy Medical Policy Manual Genetic Testing, Policy No. 41 BRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy Next Review: August 2019 Last Review: July 2018 Effective: August 1,

More information

Single Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV melanoma

Single Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV melanoma Single Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment:

More information

MAPK Pathway. CGH Next Generation Sequencing. Molecular Tools in Care of Patients with Pigmented Lesions 7/20/2017

MAPK Pathway. CGH Next Generation Sequencing. Molecular Tools in Care of Patients with Pigmented Lesions 7/20/2017 Molecular Tools in Care of Patients with Pigmented Lesions Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Tammie Ferringer,

More information

Challenges in Melanoma Diagnosis and Management

Challenges in Melanoma Diagnosis and Management Challenges in Melanoma Diagnosis and Management Winter Clinical Dermatology Conference - Hawaii Darrell S. Rigel, MD MS Clinical Professor of Dermatology New York University Medical Center DISCLOSURE OF

More information

New Systemic Therapies in Advanced Melanoma

New Systemic Therapies in Advanced Melanoma New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity

More information

Novel Therapies in Melanoma the Immunotherapy Approach

Novel Therapies in Melanoma the Immunotherapy Approach 2018 AAD Annual Meeting, San Diego, CA Novel Therapies in Melanoma the Immunotherapy Approach Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion & Melanoma Program Physician

More information

What's New in Oncodermatopathology: Immunotherapy Reactions

What's New in Oncodermatopathology: Immunotherapy Reactions What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March

More information

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current

More information

Best Practices in the Treatment and Management of Metastatic Melanoma. Melanoma

Best Practices in the Treatment and Management of Metastatic Melanoma. Melanoma Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant

More information

A New Era In Treatment Of Malignant Melanoma: Biological therapies

A New Era In Treatment Of Malignant Melanoma: Biological therapies A New Era In Treatment Of Malignant Melanoma: Biological therapies Anila Kirt, Jingjun Zhao Department of Dermatology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China A

More information

Melanoma in Focus: Update on Novel Therapy, Emerging Agents, and Optimizing Patient Care Presentation 1

Melanoma in Focus: Update on Novel Therapy, Emerging Agents, and Optimizing Patient Care Presentation 1 Presentation 1 The following is a transcript from a web-based CME -certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational

More information

Sentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma

Sentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma Sentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma John A Zitelli MD Adjunct Clinical Associate Professor Dermatology, Otolaryngology, Plastic Surgery University of Pittsburgh

More information

Update on Targeted Therapy in Melanoma

Update on Targeted Therapy in Melanoma Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1

More information

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical

More information

2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los

More information

Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3

Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Vemurafenib (Zelboraf) for Advanced Melanoma October 1, 2012

pan-canadian Oncology Drug Review Final Clinical Guidance Report Vemurafenib (Zelboraf) for Advanced Melanoma October 1, 2012 pan-canadian Oncology Drug Review Final Clinical Guidance Report Vemurafenib (Zelboraf) for Advanced Melanoma October 1, 2012 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

More information

Update on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS

Update on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph

More information

You Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018

You Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018 You Are Going to Cut How Much Skin? Locoregional Surgical Treatment Justin Rivard MD, MSc, FRCSC September 21, 2018 Presenter Disclosure Faculty/Speaker: Justin Rivard Relationships with financial sponsors:

More information

Management of Brain Metastases Sanjiv S. Agarwala, MD

Management of Brain Metastases Sanjiv S. Agarwala, MD Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):

More information

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,

More information

Update on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017

Update on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single

More information

DISCLOSURES WHAT S NEW AND EXCITING FROM JAAD

DISCLOSURES WHAT S NEW AND EXCITING FROM JAAD WHAT S NEW AND EXCITING FROM JAAD Bruce H. Thiers, MD, Editor, JAAD Professor, Medical University of South Carolina Department of Dermatology and Dermatologic Surgery DISCLOSURES PFIZER VALEANT EFFECT

More information

Melanoma: Early Detection and Therapeutic Progress

Melanoma: Early Detection and Therapeutic Progress Melanoma: Early Detection and Therapeutic Progress David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Surgery Thanks to my collaborators, mentors and patients May 19, 2017 Disclosures:

More information

Normal RAS-RAF (MAPK) pathway signaling

Normal RAS-RAF (MAPK) pathway signaling BRAF-Mutations in Melanomas L. Mazzucchelli Istituto Cantonale di Patologia, Locarno 77. Annual Meeting Swiss Society of Pathology, Lucerne 2011 Sponsored by Roche Pharma Switzerland Melanoma has increased

More information

Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011

Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011 Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011 Most common form of cancer in adults ages 25-29 3-5% of skin cancers but 65-75% of deaths Most common metastasis to small

More information

General Information, efficacy and safety data

General Information, efficacy and safety data Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie

More information

Epidemiology. Objectives 8/28/2017

Epidemiology. Objectives 8/28/2017 Case based Discussion of Head and Neck Melanoma: Review of Epidemiology, Risk Factors, Identification, Treatments and Prevention Jacqueline M. Doucette MS FNP-C Objectives Define and identify melanoma

More information

Tafinlar. Tafinlar (dabrafenib) Description

Tafinlar. Tafinlar (dabrafenib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.37 Subject: Tafinlar Page: 1 of 8 Last Review Date: September 20, 2018 Tafinlar Description Tafinlar

More information

Immunotherapy of Melanoma Sanjiv S. Agarwala, MD

Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma

More information

PREVENTION & SCREENING

PREVENTION & SCREENING MELANOMA Updated May 2018 by: Dr. Michael Herman (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by: Dr. Sudha Rajagopal (Medical Oncologist, Carlo Fidani Regional Cancer Centre, University

More information

MELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone

MELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year

More information

Emerging Trends & Strategies in the Treatment & Management of Metastatic Melanoma. Evan J. Lipson, MD

Emerging Trends & Strategies in the Treatment & Management of Metastatic Melanoma. Evan J. Lipson, MD Emerging Trends & Strategies in the Treatment & Management of Metastatic Melanoma Evan J. Lipson, MD Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center April 25, 2014

More information

Surgical Treatment of Melanoma Across the Disease Spectrum:

Surgical Treatment of Melanoma Across the Disease Spectrum: AOCD Annual Fall Meeting October 28 th, 2017 New Orleans, Louisiana Surgical Treatment of Melanoma Across the Disease Spectrum: Standards of Care and Evolving Paradigms Merrick Ross, M.D. Professor of

More information

Case Report Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation

Case Report Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation Case Reports in Oncological Medicine Volume 2016, Article ID 2672671, 4 pages http://dx.doi.org/10.1155/2016/2672671 Case Report Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic

More information

Hosts. Anees Chagpar, MD Associate Professor of Surgical Oncology. Steven Gore, MD Director of Hematological Malignancies. Melanoma Awareness 2015

Hosts. Anees Chagpar, MD Associate Professor of Surgical Oncology. Steven Gore, MD Director of Hematological Malignancies. Melanoma Awareness 2015 Hosts Anees, MD Associate Professor of Surgical Oncology Steven Gore, MD Director of Hematological Malignancies Melanoma Awareness 2015 Guest Experts: Jennifer, MD Assistant Professor of Dermatology; Director,

More information

Emerging Targets in Immunotherapy

Emerging Targets in Immunotherapy Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy

More information

New Therapeutic Approaches to Malignant Melanoma

New Therapeutic Approaches to Malignant Melanoma 2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational

More information

Surgical Issues in Melanoma

Surgical Issues in Melanoma Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical

More information

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures

More information

Combination Approaches in Melanoma: A Balancing Act

Combination Approaches in Melanoma: A Balancing Act Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic

More information

Medical Treatment for Melanoma Sanjiv S. Agarwala, MD

Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview

More information

NEW SURGICAL APPROACHES TO MELANOMA THERAPY

NEW SURGICAL APPROACHES TO MELANOMA THERAPY NEW SURGICAL APPROACHES TO MELANOMA THERAPY Melanoma 2003: New Insights Into Therapy & Treatment Douglas L. Fraker, M.D. University of Pennsylvania Surgical Treatment of Melanoma Primary resection margins

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Gene Expression Profiling for Cutaneous Melanoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gene_expression_profiling_for_cutaneous_melanoma 5/2018

More information

Association of wait times to surgical, medical and radiation therapies with overall survival in Ontarians with melanoma

Association of wait times to surgical, medical and radiation therapies with overall survival in Ontarians with melanoma Association of wait times to surgical, medical and radiation therapies with overall survival in Ontarians with melanoma Alyson Crawford Thesis submitted to the Faculty of Graduate and Postdoctoral Studies

More information

BRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma

BRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma QUALITY OF LIFE IN ONCOLOGY Review article BRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma Maksymilian Kruczała, Aleksandra Grela-Wojewoda, Marek Ziobro Clinic of Systemic and Metastatic

More information

BRAF Inhibition in Melanoma

BRAF Inhibition in Melanoma BRAF Inhibition in Melanoma New York City, Mar 22-23, 2013 Bartosz Chmielowski, MD, PhD Assistant Clinical Professor University of California Los Angeles Disclosures Speaker Bureau: BMS, Genentech, Prometheus

More information

23/04/2015. Recent advances in Melanoma and Non Melanoma Skin Cancer

23/04/2015. Recent advances in Melanoma and Non Melanoma Skin Cancer Recent advances in and Non Skin Cancer Rodney Sinclair Professor of Dermatology University of Melbourne & Epworth Hospital 86.5% increase 120% increase 37.5% increase 1 To ascertain incidence of NMSC De

More information

Melanoma: What else beyond Checkpoint Inhibitor pathway?

Melanoma: What else beyond Checkpoint Inhibitor pathway? Melanoma: What else beyond Checkpoint Inhibitor pathway? Jose Lutzky MD, FACP Director, Mount Sinai Melanoma Program Miami Beach, Florida Clinical Associate Professor, Wertheim School of Medicine, FIU,

More information

BRAF Gene Mutation Testing To Select Melanoma Patients for BRAF Inhibitor Targeted Therapy. Original Policy Date

BRAF Gene Mutation Testing To Select Melanoma Patients for BRAF Inhibitor Targeted Therapy. Original Policy Date MP 2.04.66 BRAF Gene Mutation Testing To Select Melanoma Patients for BRAF Inhibitor Targeted Therapy Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date

More information

2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO

2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO 2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers

More information

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma Section Editors: Christopher J. Campen and Beth Eaby-Sandy Pembrolizumab: First in Class for Treatment of Metastatic Melanoma CARRIE BARNHART, PharmD From Billings Clinic Cancer Center, Billings, Montana

More information

Dr Rosalie Stephens. Mr Richard Martin. Medical Oncologist Auckland City Hospital Auckland

Dr Rosalie Stephens. Mr Richard Martin. Medical Oncologist Auckland City Hospital Auckland Dr Rosalie Stephens Medical Oncologist Auckland City Hospital Auckland Mr Richard Martin General Surgeon Melanoma Unit Team Waitemata District Health Board Auckland 8:30-9:25 WS #99: Interactive Case Studies

More information

Surgical Oncology Perspective of Melanoma

Surgical Oncology Perspective of Melanoma Surgical Oncology Perspective of Melanoma Hans F. Schoellhammer, MD, FACS Assistant Clinical Professor Division of Surgical Oncology September 20, 2018 Nothing to disclose DISCLOSURE Discussion Objectives

More information

Patient Selection and Sequencing of Therapies in the New Melanoma Landscape

Patient Selection and Sequencing of Therapies in the New Melanoma Landscape Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

ONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing

ONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma

More information

Oral Chemotherapy Agents

Oral Chemotherapy Agents Oral Chemotherapy Agents NEW ADVANCES IN TARGETED THERAPY, OVERCOMING BARRIERS AND PROMOTING ADHERENCE KATIE SIAS, PHARMD CLINICAL PHARMACY COORDINATOR HEMATOLOGY/ONCOLOGY MIDMICHIGAN MEDICAL CENTER -

More information

We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications

We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Cone Health Disclosures Merck Pharmaceuticals Speaker s Bureau 1 Objectives

More information

Identification of BRAF mutations in melanoma lesions with the Roche z480 instrument

Identification of BRAF mutations in melanoma lesions with the Roche z480 instrument Identification of BRAF mutations in melanoma lesions with the Roche z480 instrument Márta Széll IAP, Siófok May 14, 2012 Multifactorial skin diseses: much more frequent then genodermatoses exhibit familial

More information

Nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316] STA Lead team presentation: Cost Effectiveness Part 1

Nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316] STA Lead team presentation: Cost Effectiveness Part 1 For public no AIC or CIC Nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316] STA Lead team presentation: Cost Effectiveness Part 1 1st Appraisal Committee meeting Committee

More information

New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy

New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic BRAF V600 mutation-positive melanoma mutation-positive melanoma

More information

Service Line: Rapid Response Service Version: 1.0 Publication Date: October 18, 2017 Report Length: 20 Pages

Service Line: Rapid Response Service Version: 1.0 Publication Date: October 18, 2017 Report Length: 20 Pages CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL BRAF Targeted Therapy after Immunotherapy for Patients with Metastatic Melanoma: A Review of Clinical Effectiveness Service Line: Rapid Response

More information

Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib

Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib 670368CMSXXX10.1177/1203475416670368Journal of Cutaneous Medicine and SurgeryLacroix and Wang research-article2016 Original Article Prospective Case Series of Cutaneous Adverse Effects Associated With

More information

BRAF Gene Variant Testing To Select Melanoma or Glioma Patients for Targeted Therapy

BRAF Gene Variant Testing To Select Melanoma or Glioma Patients for Targeted Therapy BRAF Gene Variant Testing To Select Melanoma or Glioma Patients for Targeted Therapy Policy Number: 2.04.77 Last Review: 12/2018 Origination: 4/2013 Next Review: 12/2019 Policy Blue Cross and Blue Shield

More information